Physician profile
Kosunarty Fa
NPI 1114912839
$3,621.81
in general payments reported to CMS, 2019-2025
40 companies · $853 in 2025
The $853 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.24 · 2020: $284 · 2021: $460 · 2022: $548 · 2023: $557 · 2024: $883 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,291 · Education: $2.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,290.79 |
| Education | $2.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,011.24 | 2020-2025 | Farxiga, Lokelma |
| Amgen INC. | $481.47 | 2024-2025 | Krystexxa, Tavneos |
| Merck Sharp & Dohme LLC | $453.59 | 2023-2025 | Prevymis, Dificid |
| Fresenius USA Marketing, INC. | $139.14 | 2024 | Nxstage System One |
| Novo Nordisk INC | $135.01 | 2021-2025 | Ozempic, Rybelsus, Rivfloza |
| Otsuka America Pharmaceutical, INC. | $129.79 | 2022-2025 | Jynarque |
| Nxstage Medical, INC. | $105.01 | 2022-2024 | |
| Glaxosmithkline, LLC. | $100.11 | 2021-2023 | Benlysta |
| Mallinckrodt Hospital Products INC. | $86.58 | 2021-2024 | Acthar |
| Veloxis Pharmaceuticals, INC. | $80.75 | 2020-2022 | |
| Travere Therapeutics, INC. | $75.18 | 2019-2025 | Filspari |
| Horizon Therapeutics Plc | $74.60 | 2022-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.73 | 2022-2025 | Jardiance |
| Cormedix INC. | $62.39 | 2024-2025 | Defencath, Defencath |
| Takeda Pharmaceuticals U.S.A., INC. | $43.58 | 2022-2025 | Livtencity |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kosunarty Fa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.